XERS
Price
$4.70
Change
-$0.04 (-0.84%)
Updated
Jun 27 closing price
Capitalization
752.73M
39 days until earnings call
XNCR
Price
$8.14
Change
-$0.26 (-3.10%)
Updated
Jun 27 closing price
Capitalization
579.33M
32 days until earnings call
Interact to see
Advertisement

XERS vs XNCR

Header iconXERS vs XNCR Comparison
Open Charts XERS vs XNCRBanner chart's image
Xeris Biopharma Holdings
Price$4.70
Change-$0.04 (-0.84%)
Volume$4.69M
Capitalization752.73M
Xencor
Price$8.14
Change-$0.26 (-3.10%)
Volume$1.62M
Capitalization579.33M
XERS vs XNCR Comparison Chart in %
Loading...
XERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
XERS vs. XNCR commentary
Jun 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is XERS is a Buy and XNCR is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 29, 2025
Stock price -- (XERS: $4.70 vs. XNCR: $8.14)
Brand notoriety: XERS and XNCR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: XERS: 215% vs. XNCR: 171%
Market capitalization -- XERS: $752.73M vs. XNCR: $579.33M
XERS [@Biotechnology] is valued at $752.73M. XNCR’s [@Biotechnology] market capitalization is $579.33M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

XERS’s FA Score shows that 0 FA rating(s) are green whileXNCR’s FA Score has 1 green FA rating(s).

  • XERS’s FA Score: 0 green, 5 red.
  • XNCR’s FA Score: 1 green, 4 red.
According to our system of comparison, XNCR is a better buy in the long-term than XERS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

XERS’s TA Score shows that 5 TA indicator(s) are bullish while XNCR’s TA Score has 2 bullish TA indicator(s).

  • XERS’s TA Score: 5 bullish, 3 bearish.
  • XNCR’s TA Score: 2 bullish, 7 bearish.
According to our system of comparison, XERS is a better buy in the short-term than XNCR.

Price Growth

XERS (@Biotechnology) experienced а +4.21% price change this week, while XNCR (@Biotechnology) price change was -4.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

XERS is expected to report earnings on Aug 06, 2025.

XNCR is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XERS($753M) has a higher market cap than XNCR($579M). XERS YTD gains are higher at: 38.643 vs. XNCR (-64.578). XERS has higher annual earnings (EBITDA): -4.34M vs. XNCR (-161.68M). XNCR has more cash in the bank: 470M vs. XERS (58.4M). XNCR has less debt than XERS: XNCR (67.8M) vs XERS (269M). XERS has higher revenues than XNCR: XERS (223M) vs XNCR (127M).
XERSXNCRXERS / XNCR
Capitalization753M579M130%
EBITDA-4.34M-161.68M3%
Gain YTD38.643-64.578-60%
P/E RatioN/AN/A-
Revenue223M127M176%
Total Cash58.4M470M12%
Total Debt269M67.8M397%
FUNDAMENTALS RATINGS
XERS vs XNCR: Fundamental Ratings
XERS
XNCR
OUTLOOK RATING
1..100
868
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
78
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
4265
P/E GROWTH RATING
1..100
1004
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XNCR's Valuation (78) in the Biotechnology industry is in the same range as XERS (91) in the Pharmaceuticals Major industry. This means that XNCR’s stock grew similarly to XERS’s over the last 12 months.

XNCR's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as XERS (100) in the Pharmaceuticals Major industry. This means that XNCR’s stock grew similarly to XERS’s over the last 12 months.

XNCR's SMR Rating (97) in the Biotechnology industry is in the same range as XERS (100) in the Pharmaceuticals Major industry. This means that XNCR’s stock grew similarly to XERS’s over the last 12 months.

XERS's Price Growth Rating (42) in the Pharmaceuticals Major industry is in the same range as XNCR (65) in the Biotechnology industry. This means that XERS’s stock grew similarly to XNCR’s over the last 12 months.

XNCR's P/E Growth Rating (4) in the Biotechnology industry is significantly better than the same rating for XERS (100) in the Pharmaceuticals Major industry. This means that XNCR’s stock grew significantly faster than XERS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
XERSXNCR
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
68%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
83%
MACD
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 9 days ago
71%
Declines
ODDS (%)
N/A
Bearish Trend 2 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
69%
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
XERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CEYRX96.770.47
+0.49%
Calvert Equity R6
HSZCX3.080.01
+0.33%
NexPoint Climate Tech C
IMCGX11.150.03
+0.27%
Transamerica Mid Cap Growth I
SABTX22.690.05
+0.22%
SA US Value
MSCMX16.56N/A
N/A
Morgan Stanley Insight C

XERS and

Correlation & Price change

A.I.dvisor indicates that over the last year, XERS has been loosely correlated with TRDA. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if XERS jumps, then TRDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XERS
1D Price
Change %
XERS100%
-0.84%
TRDA - XERS
51%
Loosely correlated
-1.57%
YMAB - XERS
45%
Loosely correlated
-2.08%
XNCR - XERS
45%
Loosely correlated
-3.10%
CGON - XERS
44%
Loosely correlated
-0.46%
KRYS - XERS
43%
Loosely correlated
-2.60%
More

XNCR and

Correlation & Price change

A.I.dvisor indicates that over the last year, XNCR has been loosely correlated with CRNX. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if XNCR jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XNCR
1D Price
Change %
XNCR100%
-3.10%
CRNX - XNCR
58%
Loosely correlated
-1.48%
BEAM - XNCR
56%
Loosely correlated
-1.98%
KRYS - XNCR
55%
Loosely correlated
-2.60%
BCYC - XNCR
55%
Loosely correlated
-0.55%
SYRE - XNCR
55%
Loosely correlated
-4.99%
More